• 11-AUG-2014

  • SOURCE: Novo Nordisk A/S

NOT INTENDED FOR UK MEDIA<br><br> <I>Diabetes Care</I> publishes phase 3a data demonstrating safety and efficacy of IDegLira in people with type 2 diabetes uncontrolled on basal insulin

Novo Nordisk Logo
Diabetes Care publishes phase 3a findings from the DUAL™ II trial investigating IDegLira, the once-daily combination of Tresiba® (insulin degludec) and Victoza® (liraglutide) in one pen for people with type 2 diabetes switching from basal insulin therapy. Data from the DUAL™ II trial demonstrated a statistically significant greater glucose-lowering effect with IDegLira than insulin degludec at equivalent insulin doses. Weight loss and a low rate of hypoglycaemia were comparable to insulin degludec.

IDegLira demonstrated a mean HbA1c (blood glucose) reduction of 1.9% from baseline, versus 0.9% with insulin degludec at equivalent insulin doses (45 units). 60% of people treated with IDegLira achieved a HbA1c goal of ˂7.0% compared to 23% treated with insulin degludec. At the end of trial, 40% of the people who met HbA1c goal did so with no confirmed hypoglycaemic episodes and with no weight gain, compared to 8.5% of people treated with insulin degludec. People treated with IDegLira had a statistically significant mean weight loss of 2.7 kg from baseline compared to no change with insulin degludec at the end of the trial (p<0.0001).